TWI455941B - 純化十字孢靈素之方法 - Google Patents

純化十字孢靈素之方法 Download PDF

Info

Publication number
TWI455941B
TWI455941B TW101122882A TW101122882A TWI455941B TW I455941 B TWI455941 B TW I455941B TW 101122882 A TW101122882 A TW 101122882A TW 101122882 A TW101122882 A TW 101122882A TW I455941 B TWI455941 B TW I455941B
Authority
TW
Taiwan
Prior art keywords
staurosporine
purifying
alcohol solvent
suspension
purifying staurosporine
Prior art date
Application number
TW101122882A
Other languages
English (en)
Chinese (zh)
Other versions
TW201247681A (en
Inventor
Pascale Hoehn
Bernd Koch
Michael Mutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35501294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI455941(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TW201247681A publication Critical patent/TW201247681A/zh
Application granted granted Critical
Publication of TWI455941B publication Critical patent/TWI455941B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Peptides Or Proteins (AREA)
TW101122882A 2004-11-05 2005-11-04 純化十字孢靈素之方法 TWI455941B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62534304P 2004-11-05 2004-11-05
US64213105P 2005-01-07 2005-01-07

Publications (2)

Publication Number Publication Date
TW201247681A TW201247681A (en) 2012-12-01
TWI455941B true TWI455941B (zh) 2014-10-11

Family

ID=35501294

Family Applications (4)

Application Number Title Priority Date Filing Date
TW101122882A TWI455941B (zh) 2004-11-05 2005-11-04 純化十字孢靈素之方法
TW094138677A TWI433852B (zh) 2004-11-05 2005-11-04 N－苄醯基－十字孢靈素之結晶形、其製備方法及其用途
TW101122880A TWI530500B (zh) 2004-11-05 2005-11-04 非晶形ｎ-苄醯基-十字孢靈素、其製備方法及其用途
TW103130302A TWI530501B (zh) 2004-11-05 2005-11-04 純化十字孢靈素之方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
TW094138677A TWI433852B (zh) 2004-11-05 2005-11-04 N－苄醯基－十字孢靈素之結晶形、其製備方法及其用途
TW101122880A TWI530500B (zh) 2004-11-05 2005-11-04 非晶形ｎ-苄醯基-十字孢靈素、其製備方法及其用途
TW103130302A TWI530501B (zh) 2004-11-05 2005-11-04 純化十字孢靈素之方法

Country Status (31)

Country Link
US (2) US8198435B2 (https=)
EP (3) EP2272850B1 (https=)
JP (4) JP5057986B2 (https=)
KR (3) KR101333851B1 (https=)
CN (2) CN102993213A (https=)
AR (1) AR052322A1 (https=)
AU (2) AU2005300693B2 (https=)
BR (1) BRPI0517689A (https=)
CA (1) CA2584911C (https=)
CY (1) CY1113059T1 (https=)
DK (1) DK1812448T3 (https=)
EC (1) ECSP12007431A (https=)
ES (1) ES2388142T3 (https=)
GT (1) GT200500311A (https=)
HK (1) HK1211587A1 (https=)
HR (1) HRP20120652T1 (https=)
IL (3) IL182691A (https=)
JO (1) JO2897B1 (https=)
MA (1) MA29033B1 (https=)
MX (2) MX346525B (https=)
MY (2) MY154878A (https=)
NO (2) NO338960B1 (https=)
NZ (3) NZ554653A (https=)
PE (3) PE20060947A1 (https=)
PL (1) PL1812448T3 (https=)
PT (1) PT1812448E (https=)
RU (2) RU2394038C2 (https=)
SI (1) SI1812448T1 (https=)
TN (1) TNSN07165A1 (https=)
TW (4) TWI455941B (https=)
WO (1) WO2006048296A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2454220C2 (ru) 2006-08-16 2012-06-27 Новартис Аг Способ получения твердых дисперсий высококристаллических терапевтических соединений
EP2327706A1 (en) 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
KR20160008267A (ko) 2014-07-14 2016-01-22 주식회사 윈스 네트워크 기반 영상감시체계에서의 사용자 행위 분석 시스템
EP3592749A1 (en) * 2017-03-06 2020-01-15 Teva Pharmaceutical Works Ltd. Solid state forms of midostaurin
WO2019215759A1 (en) * 2018-05-09 2019-11-14 Alaparthi Lakshmi Prasad An improved process for preparation of midostaurin
IT201900004729A1 (it) 2019-03-29 2020-09-29 Procos Spa Processo per la preparazione di midostaurina ad elevato grado di purezza
WO2020261293A1 (en) * 2019-06-24 2020-12-30 Dr. Reddy's Laboratories Limited Process for preparation of midostaurin
IT201900014346A1 (it) * 2019-08-08 2021-02-08 Procos Spa Processo per la preparazione di midostaurina amorfa con un basso contenuto di solvente organico residuo
IT202000004291A1 (it) 2020-03-02 2021-09-02 Indena Spa Processo per la purificazione di alcaloidi indolo carbazolici
CN111393454A (zh) * 2020-05-07 2020-07-10 奥锐特药业(天津)有限公司 米哚妥林的新晶型及其制备方法
CN115124551B (zh) * 2021-03-24 2024-04-30 奥锐特药业(天津)有限公司 一种高纯度米哚妥林的制备方法
WO2023205504A1 (en) * 2022-04-22 2023-10-26 Rutgers, The State University Of New Jersey Formulations and methods for treating epidermolysis bullosa simplex and related conditions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107297A (en) * 1976-12-11 1978-08-15 The Kitasato Institute Antibiotic compound
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60185719A (ja) 1984-03-06 1985-09-21 Ajinomoto Co Inc 抗腫瘍剤
IL86632A0 (en) * 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5073633A (en) * 1989-03-23 1991-12-17 Bristol-Myers Company BMY-41950 antitumor antibiotic
US5096330A (en) * 1990-06-21 1992-03-17 M-B-W Inc. Pitch control mechanism for a surface finishing machine
JPH05247055A (ja) * 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
JPH05247955A (ja) 1992-03-06 1993-09-24 Taisei Corp 擁壁の施工方法
DE69326388T2 (de) 1992-06-22 1999-12-30 Kyowa Hakko Kogyo Co., Ltd. Verfahren zur Herstellung von Staurosporin-Derivaten
AU2565895A (en) * 1994-06-01 1995-12-21 Ciba-Geigy Ag Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
RU2191175C2 (ru) * 1995-12-11 2002-10-20 Сефалон, Инкорпорейтед Конденсированные изоиндолоны в качестве ингибиторов протеинкиназы с
BR9917475B1 (pt) 1999-08-30 2013-07-23 processo para a manufatura de compostos, e, modificação do processo.
EP1372611B1 (en) 2001-03-26 2006-05-17 Novartis AG Pharmaceutical composition comprising a poorly water-soluble staurosporine, a surfactant and a water-soluble polymer
KR100407758B1 (ko) 2001-08-27 2003-12-01 씨제이 주식회사 스타틴의 제조에 있어서 락톤화 방법
US7608420B2 (en) 2003-04-22 2009-10-27 Lonza Ag Process for the recovery of staurosporine from a fermentation broth

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107297A (en) * 1976-12-11 1978-08-15 The Kitasato Institute Antibiotic compound
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen

Also Published As

Publication number Publication date
KR20120101601A (ko) 2012-09-13
HK1108881A1 (en) 2008-05-23
IL182691A0 (en) 2007-09-20
DK1812448T3 (da) 2012-08-27
US8710216B2 (en) 2014-04-29
TW201247681A (en) 2012-12-01
NO20161152A1 (no) 2007-05-30
NO340404B1 (no) 2017-04-18
PE20090433A1 (es) 2009-05-05
TNSN07165A1 (en) 2008-11-21
AR052322A1 (es) 2007-03-14
TWI530501B (zh) 2016-04-21
KR20070083979A (ko) 2007-08-24
CA2584911C (en) 2017-10-24
JP5701246B2 (ja) 2015-04-15
JP2017061578A (ja) 2017-03-30
US8198435B2 (en) 2012-06-12
AU2009245817A1 (en) 2009-12-24
WO2006048296A1 (en) 2006-05-11
IL207702A0 (en) 2010-12-30
RU2007120695A (ru) 2008-12-10
KR20120101600A (ko) 2012-09-13
TW200628474A (en) 2006-08-16
NZ554653A (en) 2010-10-29
EP2272850B1 (en) 2017-05-10
JP2015063569A (ja) 2015-04-09
EP2955186A1 (en) 2015-12-16
MA29033B1 (fr) 2007-11-01
BRPI0517689A (pt) 2008-10-14
EP1812448B1 (en) 2012-05-23
JP2012149099A (ja) 2012-08-09
CY1113059T1 (el) 2016-04-13
AU2009245817B2 (en) 2013-02-21
RU2009137788A (ru) 2011-04-20
PE20060947A1 (es) 2006-10-30
EP2272850A3 (en) 2011-09-21
JO2897B1 (en) 2015-09-15
US20090137552A1 (en) 2009-05-28
ECSP12007431A (es) 2012-06-29
CN102627658A (zh) 2012-08-08
GT200500311A (es) 2006-05-22
RU2394038C2 (ru) 2010-07-10
TW201247680A (en) 2012-12-01
CN102993213A (zh) 2013-03-27
NO338960B1 (no) 2016-11-07
AU2005300693B2 (en) 2010-08-19
MX346525B (es) 2017-03-23
TWI530500B (zh) 2016-04-21
EP1812448A1 (en) 2007-08-01
PE20130377A1 (es) 2013-04-03
TW201446773A (zh) 2014-12-16
IL207702A (en) 2016-09-29
MX2007005429A (es) 2007-05-18
KR101333851B1 (ko) 2013-11-27
IL217571A (en) 2017-07-31
US20120322789A1 (en) 2012-12-20
HK1211587A1 (en) 2016-05-27
TWI433852B (zh) 2014-04-11
JP5057986B2 (ja) 2012-10-24
KR101289998B1 (ko) 2013-07-30
PL1812448T3 (pl) 2012-10-31
HRP20120652T1 (hr) 2012-09-30
PT1812448E (pt) 2012-08-24
JP2008518995A (ja) 2008-06-05
SI1812448T1 (sl) 2012-09-28
CA2584911A1 (en) 2006-05-11
RU2467012C2 (ru) 2012-11-20
KR101265850B1 (ko) 2013-05-20
NO20072290L (no) 2007-05-30
IL182691A (en) 2013-02-28
MY147404A (en) 2012-11-30
AU2005300693A1 (en) 2006-05-11
EP2272850A2 (en) 2011-01-12
NZ588025A (en) 2012-04-27
MY154878A (en) 2015-08-14
NZ599033A (en) 2012-09-28
ES2388142T3 (es) 2012-10-09

Similar Documents

Publication Publication Date Title
TWI455941B (zh) 純化十字孢靈素之方法
JP2007522094A5 (https=)
JP2007518723A5 (https=)
NO345018B1 (no) Framgangsmåte for framstilling av organofluorforbindelser i alkoholholdige løsningsmidler.
JP2006519232A5 (https=)
CA2403152A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
DE50106698D1 (de) Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE602005024206D1 (de) Verfahren zur Herstellung von hydrophilen Kohlenstoffnanoröhren
ATE416766T1 (de) Verfahren zur herstellung von 4-(2- dipropylaminoethyl)-1,3-dihydro-2h-indol-2-on- hydrochlorid
NO20070188L (no) Krystallisert polyetylentereftalat som inneholder silisium og fremgangsmate for fremstilling derav
WO2007011065A3 (en) Intermediate compound for synthesizing pharmaceutical agent and production method thereof
WO2006071130A3 (en) A process for preparation of imatinib base
DE602006013271D1 (de) Verfahren zur herstellung von 4-(phenoxy-5-methyl-pyrimidin-4-yloxy)piperidin-1-carboxylsäure-derivaten und damit zusammenhängenden verbindungen
DE60315950D1 (de) Verfahren zur Herstellung von Xylooligosacchariden
DE602004018370D1 (de) Polymorphe von 1-cyclopropyl-7-(äs,sü - 2,8-diazadicyclo ä4.3.0ü non-8-yl) -6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäurehydrochlorid und verfahren zu deren herstellung
WO2005074901A3 (en) New effector conjugates, process for their production and their pharmaceutical use
CA2534171A1 (en) Bicyclic indoline sulfonamide derivatives
ATE528301T1 (de) Verfahren zur herstellung von substituierten sulfoxidzusammensetzungen
DE69905208D1 (de) Kontinuierliches Verfahren zur Herstellung von Polyvinylacetat zum Herstellen von Polyvinylalkohol
JP2009507478A5 (https=)
KR20120129227A (ko) 신규한 헤테로방향족 화합물 및 이의 용도
JP2005017073A5 (https=)
WO2005008932A3 (en) Microporous latex membranes, related articles and methods
DE60314904D1 (de) Verfahren zur herstellung von chinoloncarboxylat-derivaten
NO20064549L (no) Anrikning av trehalose ved anvendelse av aluminosilikater

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees